ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 1247 • ACR Convergence 2021

    Plasma Cell-free DNA Is a Useful Biomarker for Tocilizumab Therapy in Rheumatoid Arthritis

    Teppei Hashimoto1, Yuichi Yokoyama2, Takahiro Yoshikawa3, Tetsuya Furukawa4, Naoto Azuma5, Akira Hashiramoto6 and Kiyoshi Matsui7, 1Hyogo College of Medicine, Kobe, Hyogo, Japan, 2Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, 3Hyogo College of Medicine, Nishinomiya, Japan, 4Hyogo college of Medicine, Nishinomiya, Hyogo, Japan, 5Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan, 6Kobe University, Kobe, Japan, 7Hyogo College of Medicine, Nishinomiya-city, Hyogo, Japan

    Background/Purpose: Endogenous DNA derived from nuclei is released into the blood circulation as cell-free DNA (cfDNA) following cell damage or death. cfDNA is associated with…
  • Abstract Number: 1444 • ACR Convergence 2021

    Baseline Factors Associated with the Development of Nausea and Alopecia over One Year in Patients Starting Methotrexate for Rheumatoid Arthritis

    Ahmad Sherbini1, James Gwinnutt1, Kimme Hyrich1 and Suzanne Verstappen2, 1University of Manchester, Manchester, United Kingdom, 2School of Social Sciences, The University of Manchester, Manchester, United Kingdom

    Background/Purpose: Methotrexate (MTX) is the first-line treatment in the management of patients with rheumatoid arthritis (RA) due to its good efficacy. However, certain adverse events,…
  • Abstract Number: 1610 • ACR Convergence 2021

    “You Can’t Touch, You Can’t Bond”: COVID-19 and Telehealth Impacts on Communication, Goals, and Experience of Care for Persons with Rheumatoid Arthritis and Their Clinicians

    Elizabeth Hulen1, Christopher Larsen2, Rachel Matsumoto2, Patricia Katz3 and Jennifer Barton4, 1VA Portland Health Care System, Portland, OR, 2Center to Improve Veteran Involvement in Care/VA Portland Health Care System, Portland, OR, 3University of California San Francisco, San Francisco, CA, 4VA Portland Health Care System/OHSU, Portland, OR

    Background/Purpose: A rapid shift to telehealth visits has been a key part of health system response to the ongoing COVID-19 pandemic. This study explores the…
  • Abstract Number: 1662 • ACR Convergence 2021

    Unrecognised, Subclinical, Structural or Functional Lung Changes in Rheumatoid Arthritis Is Associated with a Higher Risk of Developing Serious Respiratory Tract Infection

    Benjamin Worcester1, Dorothy Wang2, Susan Morton3 and Michelle Leech4, 1Monash Health, Melbourne, Australia, 2Melbourne Health, Clayton, Australia, 3Monash Health, Clayton, Australia, 4Monash Medical Centre, Australia, Australia

    Background/Purpose: The incidence of lung disease within the rheumatoid arthritis is well described and likely underestimated. Additionally, RA patients are at higher risk for developing…
  • Abstract Number: 1678 • ACR Convergence 2021

    Favorable Balance of Benefit and Harm of Long-Term, Low Dose Prednisolone Added to Standard Treatment in Rheumatoid Arthritis Patients Aged 65+: The Pragmatic, Multicenter, Placebo-Controlled GLORIA Trial

    Maarten Boers1, Linda Hartman1, Daniela Opris-Belinski2, Reinhard Bos3, Marc Kok4, Jose Pereira da Silva5, Ed Griep6, Ruth Klaasen7, Cornelia F. Allaart8, Paul Baudoin9, Hennie Raterman10, Zoltan Szekanecz11, Frank Buttgereit12, Pavol Masaryk13, L. Thomas Klausch1, Sabrina Paolino14, Annemarie Schilder3, Willem Lems15 and Maurizio Cutolo14, 1Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, 2Carol Davila University, Bucharest, Romania, 3Medical Center Leeuwarden, Leeuwarden, Netherlands, 4Maasstad Hospital, Rotterdam, Netherlands, 5University of Coimbra | UC · Clínica Universitária de Reumatologia. Faculty of Medicine, Columbia, Portugal, 6Antonius Hospital, Sneek, Netherlands, 7Meander Medical Center, Amersfoort, Netherlands, 8Leiden University Medical Center, Leiden, Netherlands, 9Reumazorg Flevoland, Emmeloord, Netherlands, 10Northwest Clinics, Alkmaar, Netherlands, 11Division of Rheumatology, University of Debrecen, Faculty of Medicine, Debrecen, Hungary, 12Charité – Universitätsmedizin Berlin, Berlin, Germany, 13National Institute for the Rheumatic Diseases, Bratislava, Slovakia, 14Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa, Italy, 15VUmc, Amsterdam, Netherlands

    Background/Purpose: Low-dose glucocorticoid (GC) therapy is widely used in rheumatoid arthritis (RA) but the balance of benefit and harm is still unclear. We studied the…
  • Abstract Number: 1694 • ACR Convergence 2021

    Sustainability of Response to Upadacitinib Among Patients with Active Rheumatoid Arthritis Refractory to Biological Disease-Modifying Anti-Rheumatic Drugs

    Ronald van Vollenhoven1, Stephen Hall2, Alvin Wells3, Sebastian Meerwein4, Yanna Song5, Jessica Suboticki5 and Roy Fleischmann6, 1Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, 2Emeritus Research and Monash University, Melbourne, Australia, Melbourne, Australia, 3Rheumatology and Immunotherapy Center, Franklin, WI, 4AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, 5AbbVie Inc., North Chicago, IL, 6Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: Sustained clinical remission (REM) is the primary treatment goal for patients with rheumatoid arthritis (RA), with low disease activity (LDA) being an appropriate target…
  • Abstract Number: 1712 • ACR Convergence 2021

    Adverse Outcomes and Rehospitalization After Delivery Among Women with Systemic Lupus Erythematosus or Rheumatoid Arthritis and Their Infants

    Julianna Sabo1, Namrata Singh2, Deborah Crane1, David Doody3, Melissa Schiff4 and Beth Mueller5, 1University of Washington, Seattle, WA, 2University of Washington, Bellevue, WA, 3Fred Hutchinson Cancer Research Center, Seattle, WA, 4University of Washington, University of New Mexico, Seattle, WA, 5Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA

    Background/Purpose: Women with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) have greater risk of adverse obstetric and birth outcomes than women without these conditions.…
  • Abstract Number: 1938 • ACR Convergence 2021

    A Phenome-Wide Association Study of Genes Associated with COVID-19 Severity Reveals Shared Genetics with Rheumatic Conditions

    Anurag Verma1, Noah Tsao1, Lauren Thomann2, Yuk-Lam Ho2, Rotonya Carr1, Dana crawford3, Jimmy efird4, Jennifer Huffman2, Adriana Hung5, Kerry Ivey2, Sudha Iyengar3, Michael Levin6, Shiuh-Wen luoh7, Julie Lynch8, Pradeep Natarajan9, Saiju Pyarajan10, alexander Bick11, Lauren Costa2, Giulio Genovese12, Richard Hauger13, Ravi madduri14, Gita Pathak15, Renato polimanti15, Benjamin Voight1, Marijana Vujkovic1, Maryam Zekavat15, Hongyu Zhao15, Marylyn Ritchie1, Kyong-Mi Chang16, Kelly Cho2, Juan casas2, Phil Tsao17, J. Michael Gaziano2, Christopher ODonnell2, Scott Damrauer1 and Katherine Liao18, 1University of Pennsylvania, Philadelphia, PA, 2VA Boston Healthcare System, Boston, MA, 3Case Western Reserve University, Cleveland, OH, 4DVAHCS, Durham, 5Vanderbilt University Medical Center, Nashville, TN, 6University of Pennsylvania, Philadelphia, 7Oregon Health & Science University, Portland, 8VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT, 9Massachusetts General Hospital, Boston, MA, 10Partners, Boston, 11Vanderbilt University, Nashville, TN, 12Harvard Medical School, Boston, MA, 13University of California San Diego, San Diego, CA, 14Argon National Lab, Chicago, IL, 15Yale University, New Haven, CT, 16VA Philadelphia, Philadelphia, PA, 17VA Palo Alto, Palo Alto, CA, 18Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Severe coronavirus disease 2019 (COVID-19) is associated with a broad range of clinical conditions. International efforts have led to the identification of risk alleles…
  • Abstract Number: 0025 • ACR Convergence 2021

    The Modulatory Capacity of Galectin-3 on the Programmed Death-1 Signaling Axis in Rheumatoid Arthritis

    Kathrine Pedersen1, Morten Aagaard Nielsen2, Malene Hvid1, Bent Deleuran1 and Stinne Greisen1, 1Aarhus University, Aarhus, Denmark, 2Aarhus University / Aarhus University Hopital, Aarhus, Denmark

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation of the synovium. Despite a variety of treatments, 30-40% of RA patients fail…
  • Abstract Number: 0041 • ACR Convergence 2021

    Vascularized ‘Synovium-on-a-Chip’ – A Novel and Adaptable Model for Dissecting Inflammatory Biology Underlying Rheumatoid Arthritis

    Theresa Wampler Muskardin1, Chao Ma2, Benteng Ma2, Kayla Van Buren3, Timothy Niewold4 and Weiqiang Chen2, 1Colton Center for Autoimmunity, NYU School of Medicine, New York, NY, 2New York University, New York, NY, 3Mnemo Therapeutics, New York, NY, 4Colton Center for Autoimmunity NYU School of Medicine, New York, NY

    Background/Purpose: Rheumatoid arthritis (RA) is a common multisystem inflammatory condition, affecting approximately 1% of the world population. The mechanisms underlying RA are still incompletely defined…
  • Abstract Number: 0141 • ACR Convergence 2021

    Who Gets Influenza Vaccinations Prior to and After a Diagnosis of RA? Results from the Canadian Early Arthritis Cohort (CATCH)

    Viviane Ta1, Orit Schieir2, Marie-France Valois1, Ines Colmegna3, Carol Hitchon4, Louis Bessette5, Glen Hazlewood6, Carter Thorne7, Janet Pope8, Gilles Boire9, Diane Tin10, Edward Keystone11, Vivian Bykerk12, Susan Bartlett1 and CATCH Investigators13, 1McGill University, Montréal, QC, Canada, 2Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, 3The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, 4University of Manitoba, Winnipeg, MB, Canada, 5Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, 6University of Calgary, Calgary, AB, Canada, 7Southlake Regional Health Centre, Newmarket, ON, Canada, 8University of Western Ontario, London, ON, Canada, 9Universite de Sherbrooke, Sherbrooke, QC, Canada, 10The Arthritis Program Research Group, Newmarket, ON, Canada, 11Keystone Consulting Enterprises Inc., Toronto, ON, Canada, 12Hospital for Special Surgery, New York, NY, 13Canadian Early Arthritis Cohort Investigators, Toronto, ON, Canada

    Background/Purpose: Annual influenza vaccination is recommended for adults with RA, but remains low in established RA. We examined influenza vaccination coverage in the year prior…
  • Abstract Number: 0228 • ACR Convergence 2021

    Optimizing Social Media as a Recruitment Tool for Hard-to-Reach Populations in Rheumatology Clinical Research

    Vladislav Tsaltskan1, Katherine Nguyen1, Christina Eaglin1, Kevin Deane2, V. Michael Holers3 and Gary Firestein1, 1University of California San Diego, San Diego, CA, 2University of Colorado Denver, Denver, CO, 3University of Colorado, Denver, CO

    Background/Purpose: Standard methods of recruitment for clinical research, such as traditional media advertisements, can be inefficient and expensive, especially for underserved communities and asymptomatic individuals.…
  • Abstract Number: 0281 • ACR Convergence 2021

    Unsupervised Machine Learning of Expanded Autoantibodies, Cytokines, and Chemokines Improves the Identification of Interstitial Lung Disease in Rheumatoid Arthritis

    Bryant England1, Dana Ascherman2, Michael Duryee1, Carlos Hunter1, Yangyuna Yang1, Punyasha Roul1, Harlan Sayles1, Fang Yu1, Jill Poole1, Joshua Baker3, Geoffrey Thiele1 and Ted Mikuls1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Pittsburgh, Pittsburgh, PA, 3University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Interstitial lung disease (ILD) frequently complicates the rheumatoid arthritis (RA) disease course, leading to significant morbidity and premature mortality. RA-ILD may be underdiagnosed or…
  • Abstract Number: 0428 • ACR Convergence 2021

    ANCA Positivity and ANCA Associated Vasculitis in Patients with Rheumatoid Arthritis

    Courtney O'Brien, Veena Ranganath and Tannaz Kermani, University of California Los Angeles, Los Angeles, CA

    Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) with rheumatoid arthritis (RA) has been reported rarely, and, studies have found ANCA positivity in RA. The…
  • Abstract Number: 0529 • ACR Convergence 2021

    COPA Syndrome-associated Mutations in Lung Transplant Recipients for Interstitial Lung Disease

    Sarah Beshay1, Isabella Osuna2, Jessica Smith1, Justin Branch3, Laura Muruato3, Marietta DeGuzman3, Pamela McShane1, Yuelan Ren1, Rajeev Singh1, Manuel Silva Carmona3, Sandeep Sahay1 and Tiphanie Vogel3, 1Houston Methodist, Houston, 2Rice University, Houston, TX, 3Baylor College of Medicine, Houston, TX

    Background/Purpose: COPA syndrome is a rare monogenic cause of immune-mediated lung disease, and it can mimic rheumatic diseases including rheumatoid arthritis (RA) with ILD, lupus…
  • « Previous Page
  • 1
  • …
  • 155
  • 156
  • 157
  • 158
  • 159
  • …
  • 219
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology